Mostrar el registro sencillo del ítem

dc.contributor.authorBande Rodriguez, Manuel Francisco 
dc.contributor.authorSantiago Varela, Maria 
dc.contributor.authorMera Yáñez, Purificación 
dc.contributor.authorPiulats, J. M.
dc.contributor.authorBlanco Teijeiro, María Jose 
dc.contributor.authorRodriguez-Alvarez, M. X.
dc.contributor.authorCapeáns Tomé, María del Carmen 
dc.contributor.authorPiñeiro Ces, Antonio 
dc.contributor.authorPardo, M.
dc.date.accessioned2017-06-07T07:03:10Z
dc.date.available2017-06-07T07:03:10Z
dc.date.issued2015
dc.identifier.issn0146-0404
dc.identifier.urihttp://hdl.handle.net/20.500.11940/2077
dc.description.abstractPURPOSE: We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycoprotein in secretomes of uveal melanoma (UM) cultures. The aim of this study was to test for the presence and levels of ME20-S in the serum of patients with choroidal nevi and UM and correlate these levels with individual clinical data. METHODS: Serum ME20-S levels were determined by ELISA in 111 patients distributed into four categories (53 choroidal nevi, 30 untreated UM, 11 10-year disease-free [DF] UM, 17 hepatic metastatic UM) and 32 age- and sex-matched controls. ME20-S levels were correlated with individual clinical data. RESULTS: The UM and the metastatic groups showed significantly higher levels of serum ME20-S than the other groups (P < 0.001). ME20-S levels in the DF patients did not differ from those in the control group. In addition, log-transformed serum ME20-S levels showed a positive correlation with the thickness of the lesion mass in UM patients (regression coefficient 0.0689, 95% confidence interval 0.0689-0.1123, R2 = 27.1%). CONCLUSIONS: Elevated ME20-S serum levels are associated with tumor size and advanced stages of UM while low levels are characteristic of DF patients. ME20-S might be a promising serum marker for UM and useful for monitoring metastatic disease.
dc.language.isoeng
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBiomarkers, Tumor
dc.subject.meshDisease Progression
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshRetrospective Studies
dc.subject.meshUveal Neoplasms
dc.subject.meshYoung Adult
dc.subject.meshgp100 Melanoma Antigen
dc.titleME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma
dc.typeArtigoes
dc.authorsophosBande, M. F.
dc.authorsophosSantiago, M.
dc.authorsophosMera, P.
dc.authorsophosPiulats, J. M.
dc.authorsophosBlanco, M. J.
dc.authorsophosRodriguez-Alvarez, M. X.
dc.authorsophosCapeans, C.
dc.authorsophosPineiro, A.
dc.authorsophosPardo, M.
dc.identifier.doi10.1167/iovs.15-17183
dc.identifier.isi368238200001
dc.identifier.pmid26523384
dc.identifier.sophos18571
dc.issue.number12
dc.journal.titleINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Oftalmoloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initial7007
dc.page.final11
dc.rights.accessRightsopenAccess
dc.subject.decsAdulto
dc.subject.decsAdulto Joven
dc.subject.decsAnciano
dc.subject.decsAnciano de 80 o más Años
dc.subject.decsAntígeno gp100 del Melanoma
dc.subject.decsBiomarcadores de Tumor
dc.subject.decsEnsayo de Inmunoadsorción Enzimática
dc.subject.decsEstudios Retrospectivos
dc.subject.decsEstudios de Seguimiento
dc.subject.decsFemenino
dc.subject.decsMelanoma
dc.subject.decsNeoplasias de la Úvea
dc.subject.decsPersona de Mediana Edad
dc.subject.decsProgresión de la Enfermedad
dc.typesophosArtículo Original
dc.volume.number56


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem